151 related articles for article (PubMed ID: 6436563)
41. Effect of antineoplastic agents on gamma-interferon production in human peripheral blood mononuclear cells.
Cesario TC; Slater LM; Kaplan HS; Gupta S; Gorse GJ
Cancer Res; 1984 Nov; 44(11):4962-6. PubMed ID: 6435860
[TBL] [Abstract][Full Text] [Related]
42. Modulation by recombinant DNA leukocyte (alpha) and fibroblast (beta) interferons of the expression and shedding of HLA- and tumor-associated antigens by human melanoma cells.
Giacomini P; Aguzzi A; Pestka S; Fisher PB; Ferrone S
J Immunol; 1984 Sep; 133(3):1649-55. PubMed ID: 6747299
[TBL] [Abstract][Full Text] [Related]
43. Suppression of human ribosomal protein L23A expression during cell growth inhibition by interferon-beta.
Jiang H; Lin JJ; Tao J; Fisher PB
Oncogene; 1997 Jan; 14(4):473-80. PubMed ID: 9053844
[TBL] [Abstract][Full Text] [Related]
44. Enhancement of antiviral activity against hepatitis C virus in vitro by interferon combination therapy.
Okuse C; Rinaudo JA; Farrar K; Wells F; Korba BE
Antiviral Res; 2005 Jan; 65(1):23-34. PubMed ID: 15652968
[TBL] [Abstract][Full Text] [Related]
45. Recombinant immune interferon down-regulates Ha-ras-1 proto-oncogene products in a human melanoma cell line.
Giacomini P; Gambari R; Barbieri R; Nastruzzi C; Fraioli R; Spandidos D; Fisher PB; Natali PG
Anticancer Res; 1990; 10(3):629-35. PubMed ID: 2114818
[TBL] [Abstract][Full Text] [Related]
46. Synergistic antiproliferative effect of recombinant alpha-interferons with recombinant gamma-interferon.
Hubbell HR; Craft JA; Leibowitz PJ; Gillespie DH
J Biol Response Mod; 1987 Apr; 6(2):141-53. PubMed ID: 3108460
[TBL] [Abstract][Full Text] [Related]
47. [Basic study on human interferon-beta: Part II. Anticellular effect].
Kanamori T; Tobita M; Horisawa Y; Nobuhara M
Gan To Kagaku Ryoho; 1986 Jun; 13(6):2105-10. PubMed ID: 3717958
[TBL] [Abstract][Full Text] [Related]
48. Natural cytotoxicity and interferon production in human cancer: deficient natural killer activity and normal interferon production in patients with advanced disease.
Kadish AS; Doyle AT; Steinhauer EH; Ghossein NA
J Immunol; 1981 Nov; 127(5):1817-22. PubMed ID: 6170674
[TBL] [Abstract][Full Text] [Related]
49. Distinct mechanisms of loss of IFN-gamma mediated HLA class I inducibility in two melanoma cell lines.
Rodríguez T; Méndez R; Del Campo A; Jiménez P; Aptsiauri N; Garrido F; Ruiz-Cabello F
BMC Cancer; 2007 Feb; 7():34. PubMed ID: 17319941
[TBL] [Abstract][Full Text] [Related]
50. Analysis of natural killer cell cytotoxicity of cancer patients treated with recombinant interferon.
Lotzová E; Savary CA; Quesada JR; Gutterman JU; Hersh EM
J Natl Cancer Inst; 1983 Nov; 71(5):903-10. PubMed ID: 6580490
[TBL] [Abstract][Full Text] [Related]
51. Cytokine toxicity and induction of NO synthase activity in cultured mouse hepatocytes.
Adamson GM; Billings RE
Toxicol Appl Pharmacol; 1993 Mar; 119(1):100-7. PubMed ID: 7682342
[TBL] [Abstract][Full Text] [Related]
52. Antiviral activity against transmissible gastroenteritis virus, and cytotoxicity, of natural porcine interferons alpha and beta.
Weingartl HM; Derbyshire JB
Can J Vet Res; 1991 Apr; 55(2):143-9. PubMed ID: 1653103
[TBL] [Abstract][Full Text] [Related]
53. Host CD4+ T lymphocytes are required for the synergistic action of interferon-alpha/beta and adoptively transferred immune cells in the inhibition of visceral ESb metastases.
Kaido TJ; Maury C; Gresser I
Cancer Res; 1995 Dec; 55(24):6133-9. PubMed ID: 8521404
[TBL] [Abstract][Full Text] [Related]
54. Interferon and retinoic acid suppress the growth of human papillomavirus type 16 immortalized cervical epithelial cells, but only interferon suppresses the level of the human papillomavirus transforming oncogenes.
Agarwal C; Hembree JR; Rorke EA; Eckert RL
Cancer Res; 1994 Apr; 54(8):2108-12. PubMed ID: 8174114
[TBL] [Abstract][Full Text] [Related]
55. Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients.
Bercovici N; Haicheur N; Massicard S; Vernel-Pauillac F; Adotevi O; Landais D; Gorin I; Robert C; Prince HM; Grob JJ; Leccia MT; Lesimple T; Wijdenes J; Bartholeyns J; Fridman WH; Salcedo M; Ferries E; Tartour E
J Immunother; 2008 Jan; 31(1):101-12. PubMed ID: 18157017
[TBL] [Abstract][Full Text] [Related]
56. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
[TBL] [Abstract][Full Text] [Related]
57. Synergistic anticellular effect of a combination of beta-interferon and retinoic acid against U937 cells.
Ho CK
Cancer Res; 1985 Nov; 45(11 Pt 1):5348-51. PubMed ID: 3863704
[TBL] [Abstract][Full Text] [Related]
58. The effect of alpha-, beta- and gamma-interferon on the growth of breast cancer cell lines.
Coradini D; Biffi A; Pirronello E; Di Fronzo G
Anticancer Res; 1994; 14(5A):1779-84. PubMed ID: 7531412
[TBL] [Abstract][Full Text] [Related]
59. Limiting dilution analysis of human peripheral blood mononuclear leukocytes that react to human amnion cells and protect these against viral challenge.
Rönnblom L; Alm GV
Eur J Immunol; 1982 May; 12(5):437-41. PubMed ID: 6178610
[TBL] [Abstract][Full Text] [Related]
60. Deficiency of interferon-gamma but not interferon-beta in Arabian foals with severe combined immunodeficiency.
Yilma T; Perryman LE; McGuire TC
J Immunol; 1982 Sep; 129(3):931-3. PubMed ID: 6180003
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
